Qualigen (QLGN) stock jumped 32% Tuesday – Is it worth the price?

Highlights

  • Qualigen Therapeutics, Inc. (NASDAQ: QLGN) soared 32% in intraday trading on Tuesday.
  • Its third-quarter revenue rose to US$US$1.16 million compared to a net loss of US$8.11 million a year ago.
  • The company develops novel therapeutic products using nanoparticle coating technology for treating infectious diseases and cancer.

The shares of Qualigen Therapeutics, Inc. (NASDAQ: QLGN) jumped more than 32% in intraday trading on Tuesday. The QLGN stock was up 32.70% to US$1.6588 at 10:49 am ET. 

The stock has been rallying since Nov 19, leaving many traders pleasantly surprised over the gains, although there had been no recent news from the company.

It is a significant development for the fans of the QLGN stock since its price has been falling this year. The QGLN shares fell 44.52% YTD but gained 17% in the last five days. 

Analysts estimate its one-year price target at US$9.00.

The Carlsbad, California-based biotechnology company declared its third-quarter results on Nov 15, 2021. The company develops novel therapeutic products using nanoparticle coating technology to treat infectious diseases and cancer.

Also Read: Five metaverse cryptos that are making news

Biotechnology company Qualigen Therapeutics, Inc. (NASDAQ: QLGN): Trending healthcare stock.

Also Read: Top food and beverages stocks to explore in Thanksgiving week

Third-quarter performance 

For the three months ended September 30, 2021, QGLN posted revenue of US$1.16 million compared to US$0.837 million for the third quarter of 2020. It booked a net loss of US$2.86 million or US$(0.10) per share diluted, compared to a net loss of US$8.11 million or US$(0.41) per share diluted for the comparable quarter in the previous year.

The net loss per share diluted was less in Q3 at US$(0.10) against a net loss per share diluted of US$(0.41) for the nine months ended September 30, 2021.  

Also Read: AeroClean Technologies (AERC) IPO: How to buy the stock?

The company reported a 38% increase in Q3, 2021 revenue, YoY, and a 30% increase in revenue in the nine months YoY. 

The cash and cash equivalents were US$12.3 million for the nine months ended on September 30, 2021, while it was US$14.47 million for the nine months ended September 30, 2020.

The healthcare company has a market capitalization of US$47 million. The QGLN stock traded in the range of US$4.66 to US$0.93 in the last 52 weeks.

Also Read: Pendo IPO: Software company gearing up for public offer?

Bottomline

The Nasdaq Biotechnology Index (NBI) declined 1.15% YTD and fell around 2.5% in the last five days. At the same time, QGLN stock fell 44.52% YTD but gained 17% in the last five days. However, investors must check the company fundamentals before investing in stocks.

Comment


Disclaimer